ClinicalTrials.gg
RecruitingNCT05704582AC2Updated Feb 7, 2024

RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders

An interventional study of Avatar Intervention and Addiction supportive intervention in Psychotic Disorders, Cannabis Use Disorder and Mental Health Disorder, sponsored by Ciusss de L'Est de l'Île de Montréal. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Ciusss de L'Est de l'Île de Montréal · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 148 studies in Psychotic Disorders with a site in Canada — 32 open to participants now, 41 under way, 2 of them phase 3. Psychotic Disorders · Canada.

Planned enrollment
18th of 117
150 · median 58
Started
2023
with 7 others
No phase
86 of 148
17 open now
Primary completion
2027-01
later than 17 of 40 live
Registered
121st of 148
by date
Lead sponsor
3 of 148
Ciusss de L'Est de l'Île de Montréal

Among the 148 studies in Psychotic Disorders with a site in Canada, this one is the 18th largest by planned enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2023, is one of 86 with no phase, reaches primary completion later than 17 of the 40 other live ones, and was the 121st registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

32 of the 148 studies in Psychotic Disorders with a site in Canada are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Psychotic Disorders with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with psychotic disorders.

Read the detailed description

Psychotic disorders (PD) are characterized by a loss of contact with reality. Cannabis use is one of the key factors leading to psychiatric re-hospitalization in PD. In these populations, cannabis use is also associated with depressive symptoms, medication non-compliance, hostility as well as reduced quality of life. Unfortunately, there is no evidence-based intervention available for the treatment of cannabis use disorder (CUD) in this population. Novel interventions for CUD are thus critically needed. Virtual reality-based therapies are a promising avenue that allow patients to try novel strategies in real time instead of having to learn abstract rules. To fill a clinical need, the investigators have created a distinctive intervention for CUD in patients with PD. The Avatar Intervention displays strong experiential and relational components that are crucially missing in conventional interventions.

Hence, the primary outcomes are reductions in cannabis use, cannabis use disorder severity, and increased quality of life. The investigators will also explore whether the greater improvements attributable to the Avatar Intervention persist in time, and perform analyses on sex/gender, motivation to change cannabis habits, psychotic relapses, and THC metabolite levels.

Noteworthily, cannabis-related hospitalizations have been identified as one of the core indicators to measure the success of cannabis legalization. As a result, there is a pressing need to design innovative interventions that could have a significant impact on this costly and prime outcome. As there is no evidence-based therapeutic options for CUD in patients with PD, the current trial will contribute to the validation of a novel approach and create new therapeutic possibilities.

03

Conditions studied

  • Psychotic Disorders
  • Cannabis Use Disorder
  • Mental Health Disorder

Keywords

  • cannabis
  • virtual reality intervention
  • psychotic disorders
  • substance use disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females over 18 years of age who meet the criteria for CUD (≥4 criteria) ;
  • Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Diagnoses will be established with the Structured Interview for DSM-5 (SCID-5).

Exclusion criteria

Exclusion Criteria:

  • Current SUD for a substance other than cannabis ;
  • Ongoing pharmacological or psychological treatment for CUD ;
  • Ongoing detoxification for cannabis withdrawal ;
  • Presence of neurological disorders ;
  • Presence of a severe and unstable physical illness ;
  • Inability to provide consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Avatar Intervention

    The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.

    Other: Avatar Intervention

  • Active comparator
    Addiction supportive intervention

    The Addiction supportive intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use.

    Other: Addiction supportive intervention

Interventions

  • OtherAvatar Intervention

    8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.

    Also known as: Avatar-CUD

  • OtherAddiction supportive intervention

    8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.

06

What researchers measure

Primary outcomes

  1. Change in cannabis use (Timeline Follow-Back)

    A standardized tool consisting of asking the patients how many joints they smoked each day of the week during the past week.

    Time frame: Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months

Secondary outcomes

  1. Change in the severity of the cannabis use disorder (Cannabis Use Problems Identification Test - CUPIT)

    16-item self-reported questionnaire assessing cannabis use and dependence; Range 3-82, higher values indicating a more severe cannabis use disorder

    Time frame: Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months

  2. Change in quality of life(Quality of Life Enjoyment and Satisfaction Questionnaire - QLESQ-SF & Quality of Life Scale - QLS)

    QLESQ-SF: 16-item self-reported scale measuring enjoyment and satisfaction experienced during the past week in various areas of daily functioning; Range 14-70, Higher values indicate a better satisfaction of life QLS: 21-item scale based on a semistructured interview designed to assess deficit symptoms; Range 0-126, higher values indicate a better quality of life

    Time frame: Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months

07

Study locations

1 of 1 sites recruiting
  • Research center of the Institut universitaire en santé mentale de Montréal
    Montreal, Quebec H1N 3M5, Canada
    Recruiting
    • Alexandre Dumais, MD, PhD · Contact
    • Alexandre Dumais, MD, PhD · Principal investigator
    • Stephane Potvin, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jan 2027, 47 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 47 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 30, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05704582
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Feb 1, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 7, 2024

Study contacts

Alexandre Dumais, MD, PhD
Contact
contact@avatar-intervention.ca
514-251-4000 ext. 3212
Alexandre Dumais, MD, PhD
principal investigator · University of Montreal, Institut universitaire en santé mentale de Montréal
Stephane Potvin, PhD
principal investigator · University of Montreal, Institut universitaire en santé mentale de Montréal
Emmanuel Stip, MD, MSc
study chair · United Arab Emirates University
Amal Abdel Baki, MD, MSc
study chair · University of Montreal, Centre hospitalier de l'Université de Montréal
Robert-Paul Juster, PhD
study chair · University of Montreal, Institut universitaire en santé mentale de Montréal
Marie-Hélène Goulet, PhD
study chair · University of Montreal, Institut universitaire en santé mentale de Montréal
Luigi De Benedictis, MD
study chair · Institut universitaire en santé mentale de Montréal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion